Savient Pharmaceuticals, Inc. Announces an Exclusive Marketing Collaboration in Germany for Soltamox for the Treatment of Hormonally Sensitive Breast Cancer.

EAST BRUNSWICK, N.J. -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), an emerging specialty pharmaceutical company engaged in developing, manufacturing and marketing pharmaceutical products that address unmet medical needs today announced the exclusive marketing agreement between their wholly-owned subsidiary, Rosemont Pharmaceuticals ("Rosemont") and O.R.C.A.PHARM GmbH to market and distribute Soltamox(R) (tamoxifen oral liquid solution) in Germany.

Tamoxifen is a cytostatic oestrogen receptor antagonist used extensively for the treatment of hormonally sensitive breast cancer. Soltamox is the only oral liquid presentation of tamoxifen licensed in the U.K. Rosemont holds a worldwide patent covering this product.

"We are exceptionally pleased to enter into this agreement with O.R.C.A.PHARM GmbH in Germany. They are well positioned to market this important niche product in the German oncology sector," said Christopher Clement, Savient's CEO & President. "Through this agreement we are continuing to build upon the company's strategy to further expand the Rosemont Pharmaceuticals business model to select countries outside the U.K."

O.R.C.A.PHARM GmbH will be responsible for the marketing and distribution of the product within Germany. Rosemont will manufacture Soltamox at its facility in Leeds, U.K. and will earn manufacturing profits on each unit produced. Additionally, Rosemont will receive profit share payments based on sales of Soltamox into the German wholesalers.

"There is an increasing awareness in the oncological community around the compliance issues with patients using tamoxifen tablets. With O.R.C.A.PHARM GmbH as the distributor and Rosemont as the producer, we are now able to present a solution to German tamoxifen prescribers," said Dr. Frank Erich Engels, Senior Vice President, Marketing and Business Development, O.R.C.A.PHARM GmbH.

In addition to the 150 ml bottles of Soltamox sold within the UK, a new 250 ml size bottle will be marketed in Germany in line with local prescribing trends.

About Rosemont Pharmaceuticals

Rosemont Pharmaceuticals is the leading developer, manufacturer and marketer of high quality oral liquid medicines in the UK. Rosemont's products are effectively marketed by a very highly trained and focused sales force comprised primarily of nursing specialists.

With over 90 oral liquid formulations, Rosemont is the U.K. Specialist in Oral Liquid Medicines, supplying both licensed and special (named patient basis) products covering a broad range of therapeutic areas, including cardiovascular, CNS, anti-infectives and oncology.

About O.R.C.A.PHARM GmbH

O.R.C.A.PHARM is a medium-sized independent German pharmaceutical company. Since its inception in 1999, O.R.C.A.PHARM has emerged as the leading provider of pharmaceuticals, medical products and services for the private oncology sector in Germany.

About Savient Pharmaceuticals, Inc.

Savient Pharmaceuticals, Inc. is engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs in both niche and wider markets. Products marketed by Savient in the United States are Oxandrin(R) (oxandrolone, USP) and Delatestryl(R) (testosterone enanthate). Savient's subsidiary, Rosemont Pharmaceuticals Limited, develops, manufactures, and markets through its own sales force oral liquid formulations of prescription products for the UK pharmaceutical market. Savient's Israeli subsidiary, Bio-Technology General (Israel) Ltd., manufactures and markets in Israel Bio-Tropin(TM) (recombinant human growth hormone), BioLon(R) (sodium hyaluronate for ophthalmic surgery), Bio-Hep-B(R) (hepatitis B vaccine), and Arthrease(TM) (sodium hyaluronate for osteoarthritis). Products marketed by Savient's licensees are Mircette(R) (oral contraceptive), and BioLon(R) in the United States, and Bio-Tropin(TM), BioLon(R), Bio-Hep-B(R), Silkis(R) (vitamin D derivative), and recombinant human insulin, in international markets. Savient's news releases and other information are available on Savient's website at www.savientpharma.com.

Arthrease is a trademark of DePuy Orthopaedics, Inc., except in Israel, where it is owned by Bio-Technology General (Israel) Ltd., Savient's wholly owned subsidiary; Mircette is a registered trademark of Organon, Inc.; Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.; Silkis is a registered trademark of Galderma S.A.

This news release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included in this report regarding Savient's expected timing of revenues and results of operations are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about Savient's business and the biopharmaceutical and specialty pharmaceutical industries in which Savient operates. Such risks and uncertainties include, but are not limited to, delay or failure in developing Prosaptide, Puricase and other product candidates; difficulties of expanding Savient's product portfolio through in-licensing; disruption of management and costs associated with the divestiture of Savient's operations in Israel; introduction of generic competition for Oxandrin; fluctuations in buying patterns of wholesalers; potential future returns of Oxandrin or other products; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of Savient's products; economic, political and other risks associated with foreign operations; risks of maintaining protection for Savient's intellectual property; risks of an adverse determination in on-going or future intellectual property or other litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries. Savient may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on Savient's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Savient makes. Savient's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that Savient may make. Savient does not assume any obligation to update any forward-looking statements.